Understanding how immune-friendly cancer-associated fibroblasts shape pancreatic cancer
Official title: Decoding the stromal niches of antigen-presenting cancer-associated fibroblast in pancreatic ductal adenocarcinoma
Funded at Ut Southwestern Medical Center · NIH-11366758 · Data updated 2026-11-12
Aimed at mapping a special type of support cell in pancreatic cancer to see how it helps the tumor hide from the immune system and resist treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $501,803 |
| NIH project number | 1R01CA303246-01A1 |
| Project ID | NIH-11366758 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic ductal adenocarcinoma, especially those whose tumors show prominent stromal components and apCAF activity.
✕Less likely to help
Early-stage findings may not directly benefit patients who do not have the specific stromal/apCAF features studied.
What this research studies
Pancreatic cancer has a rich and complex supportive tissue that helps it grow and evade therapy. This project uses advanced sequencing and cell-tracing techniques to study antigen-presenting cancer-associated fibroblasts (apCAFs) and how they interact with other immune and cancer cells within tumor niches. By identifying the signals and interactions that sustain these niches, researchers will test whether blocking apCAF formation could make treatments more effective. The study focuses on translating detailed laboratory findings toward strategies that could improve patient responses in PDAC.
Why it matters
Potential benefit: If successful, the work could lead to new ways to weaken the tumor’s defenses and improve responses to therapy for pancreatic cancer patients.
How similar studies have gone: Previous research has shown that targeting specific stromal components can alter tumor immune interactions and therapy sensitivity in pancreatic cancer, though apCAF-focused approaches are still being explored.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Huang, Huocong — Ut Southwestern Medical Center
- Study coordinator: Huang, Huocong
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.